Cargando…
Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort
PURPOSE: We aim to describe the treatment patterns and overall survival (OS) outcomes in patients receiving trastuzumab emtansine (T-DM1) for HER2-positive metastatic breast cancer (HER2+MBC) in routine clinical care. METHODS: Retrospective, whole-of-population cohort study of people initiating T-DM...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138859/ https://www.ncbi.nlm.nih.gov/pubmed/33992964 http://dx.doi.org/10.1016/j.breast.2021.05.001 |
_version_ | 1783695891242156032 |
---|---|
author | Daniels, Benjamin Kiely, Belinda E. Tang, Monica Houssami, Nehmat Lord, Sarah J. Pearson, Sallie-Anne |
author_facet | Daniels, Benjamin Kiely, Belinda E. Tang, Monica Houssami, Nehmat Lord, Sarah J. Pearson, Sallie-Anne |
author_sort | Daniels, Benjamin |
collection | PubMed |
description | PURPOSE: We aim to describe the treatment patterns and overall survival (OS) outcomes in patients receiving trastuzumab emtansine (T-DM1) for HER2-positive metastatic breast cancer (HER2+MBC) in routine clinical care. METHODS: Retrospective, whole-of-population cohort study of people initiating T-DM1 for HER2+MBC between October 2015 and May 2019 in Australia. We used dispensing claims to estimate time-to-T-DM1 initiation, duration of treatment, and treatments administered prior to and following T-DM1 therapy. We estimated OS from T-DM1 initiation and stratified results based on whether patients received first- or second-line T-DM1 treatment. We benchmarked outcomes to those reported in the pivotal, EMILIA trial. RESULTS: 345 patients initiated T-DM1: 309 as second-line therapy for HER2+MBC and 36 as first-line therapy. 51% of patients had received endocrine therapy and 98% of second-line patients received pertuzumab prior to starting T-DM1. The median age was 57 years (53 in EMILIA); median time-to-T-DM1 initiation from start of HER2-targeted therapy for HER2+MBC was 11.6 months (IQR: 7.9–16.6); median duration of T-DM1 treatment was 6.5 months (3.1–13.5; 7.6 months in EMILIA), and median OS was 19.3 months (7.9–29.5; 29.9 months in EMILIA). CONCLUSIONS: Our findings highlight differences in patient characteristics (older, more previous pertuzumab therapy) and outcomes (shorter OS) from the T-DM1 pivotal trial and provide real-world estimates that can inform patient, clinician and policy, decisions around the use of HER2-targeted therapies in routine clinical care. |
format | Online Article Text |
id | pubmed-8138859 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-81388592021-05-24 Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort Daniels, Benjamin Kiely, Belinda E. Tang, Monica Houssami, Nehmat Lord, Sarah J. Pearson, Sallie-Anne Breast Original Article PURPOSE: We aim to describe the treatment patterns and overall survival (OS) outcomes in patients receiving trastuzumab emtansine (T-DM1) for HER2-positive metastatic breast cancer (HER2+MBC) in routine clinical care. METHODS: Retrospective, whole-of-population cohort study of people initiating T-DM1 for HER2+MBC between October 2015 and May 2019 in Australia. We used dispensing claims to estimate time-to-T-DM1 initiation, duration of treatment, and treatments administered prior to and following T-DM1 therapy. We estimated OS from T-DM1 initiation and stratified results based on whether patients received first- or second-line T-DM1 treatment. We benchmarked outcomes to those reported in the pivotal, EMILIA trial. RESULTS: 345 patients initiated T-DM1: 309 as second-line therapy for HER2+MBC and 36 as first-line therapy. 51% of patients had received endocrine therapy and 98% of second-line patients received pertuzumab prior to starting T-DM1. The median age was 57 years (53 in EMILIA); median time-to-T-DM1 initiation from start of HER2-targeted therapy for HER2+MBC was 11.6 months (IQR: 7.9–16.6); median duration of T-DM1 treatment was 6.5 months (3.1–13.5; 7.6 months in EMILIA), and median OS was 19.3 months (7.9–29.5; 29.9 months in EMILIA). CONCLUSIONS: Our findings highlight differences in patient characteristics (older, more previous pertuzumab therapy) and outcomes (shorter OS) from the T-DM1 pivotal trial and provide real-world estimates that can inform patient, clinician and policy, decisions around the use of HER2-targeted therapies in routine clinical care. Elsevier 2021-05-07 /pmc/articles/PMC8138859/ /pubmed/33992964 http://dx.doi.org/10.1016/j.breast.2021.05.001 Text en © 2021 The Authors. Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Daniels, Benjamin Kiely, Belinda E. Tang, Monica Houssami, Nehmat Lord, Sarah J. Pearson, Sallie-Anne Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort |
title | Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort |
title_full | Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort |
title_fullStr | Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort |
title_full_unstemmed | Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort |
title_short | Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort |
title_sort | trastuzumab emtansine for her2-positive metastatic breast cancer: outcomes from a whole-of-population australian cohort |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138859/ https://www.ncbi.nlm.nih.gov/pubmed/33992964 http://dx.doi.org/10.1016/j.breast.2021.05.001 |
work_keys_str_mv | AT danielsbenjamin trastuzumabemtansineforher2positivemetastaticbreastcanceroutcomesfromawholeofpopulationaustraliancohort AT kielybelindae trastuzumabemtansineforher2positivemetastaticbreastcanceroutcomesfromawholeofpopulationaustraliancohort AT tangmonica trastuzumabemtansineforher2positivemetastaticbreastcanceroutcomesfromawholeofpopulationaustraliancohort AT houssaminehmat trastuzumabemtansineforher2positivemetastaticbreastcanceroutcomesfromawholeofpopulationaustraliancohort AT lordsarahj trastuzumabemtansineforher2positivemetastaticbreastcanceroutcomesfromawholeofpopulationaustraliancohort AT pearsonsallieanne trastuzumabemtansineforher2positivemetastaticbreastcanceroutcomesfromawholeofpopulationaustraliancohort |